Clinical Review · Anti-Amyloid Therapy · For Clinicians
Lecanemab vs Donanemab: Why the Amyloid Target Matters
By Brian Paquette, DO, MPH
Lecanemab preferentially binds soluble aggregated amyloid-β protofibrils; donanemab binds pyroglutamate-modified amyloid concentrated in established plaque. That single difference helps explain their different dosing, stopping rules, and MRI schedules — but it does not make either drug categorically more effective.
The clinical problem
Lecanemab (Leqembi) and donanemab (Kisunla) are anti-amyloid monoclonal antibodies for patients with mild cognitive impairment or mild dementia due to Alzheimer disease and confirmed amyloid pathology. Both substantially lower cerebral amyloid and modestly slow decline over 18 months.[1,2] Clinicians choosing between them need to understand how they differ in the amyloid species recognized, treatment cadence, stopping strategy, and MRI surveillance — differences that matter most when counseling APOE ε4 carriers, who face a higher risk of amyloid-related imaging abnormalities (ARIA). Neither drug reverses established cognitive impairment or cures Alzheimer disease.
Clinical comparison
| Feature | Lecanemab (Leqembi) | Donanemab (Kisunla) |
| Preferred amyloid target | Soluble aggregated Aβ, particularly protofibrils; also binds fibrillar plaque Aβ | N-terminally truncated pyroglutamate Aβ (N3pG-Aβ), concentrated in deposited plaques |
| Studied population | Early symptomatic AD: MCI or mild dementia with confirmed amyloid pathology | Early symptomatic AD with confirmed amyloid pathology; the pivotal trial also required tau PET criteria |
| Pivotal phase 3 result | CLARITY AD: CDR-SB −0.45 at 18 months (~27% less decline) | TRAILBLAZER-ALZ 2, overall: ~22% less decline on iADRS, ~29% on CDR-SB; greater in low/medium tau |
| Initial schedule | 10 mg/kg IV every 2 weeks for 18 months | IV every 4 weeks, titrated 350 → 700 → 1,050 → 1,400 mg |
| After initiation | Maintenance: 10 mg/kg IV every 4 weeks, or 360 mg subcutaneous weekly (Leqembi Iqlik autoinjector) | May stop once amyloid PET shows reduction to a prespecified low level |
| ARIA in pivotal trials | ARIA-E 12.6%; ARIA-H 17.3% | ARIA-E ~24%; ARIA-H ~31% (original titration) |
| Scheduled MRI | Baseline; before infusions 3, 5, 7, and 14; unscheduled if symptoms suggest ARIA | Baseline; before infusions 2, 3, 4, and 7; unscheduled if symptoms suggest ARIA |
| APOE ε4 implication | ARIA risk higher in carriers, highest in homozygotes; genotype should inform counseling | Same class effect; genotype should inform counseling |
Percent slowing is endpoint- and population-dependent. These trials were not a head-to-head comparison, so differences in percentages do not establish superiority. Dosing and MRI schedules per current U.S. labels.[9]
Members Only
This review continues for members
The remainder of this article — the full clinical reasoning, evidence-strength tables, and complete reference list — is available to APOE4 Insights members.
- Physician-authored, evidence-calibrated clinical reviews
- Explicit about what the data do and do not support
- No industry sponsorship, no supplement affiliates
$79 a year, with a 7-day free trial and a 30-day money-back guarantee. Founding members: $59/year with code FOUNDING.
Already a member? Log in
